Sep 30, 12:06 PM

Addex Therapeutics Discloses 2024 H1 and Q2 Financial Results, Stock Up 16.1% Pre-market

Addex Therapeutics has disclosed its financial results for the first half and second quarter of 2024, along with a corporate update, reporting a 16.1% pre-market increase in stock price ($ADXN).

#Addex Therapeutics

Written with ChatGPT (GPT-4o).

Sources

Bio Stocks™@BioStocks
1 year ago
$BBIO Completes Enrollment of FORTIFY, Phase 3 Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9. Study exceeded target enrollment. Topline data readout from the interim analysis expected in 2025
Open Outcrier@OpenOutcrier
1 year ago
$ADXN (+16.1% pre) Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update - GN https://t.co/k51ZdBsyIQ
Bio Stocks™@BioStocks
1 year ago
$ALT Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in MASH. Topline efficacy data expected in Q2.

Addex Therapeutics Discloses 2024 H1 and Q2 Financial Results, Stock Up 16.1% Pre-market

Sources

Additional media

Similar Stories